ZLAB Stock Recent News

Zai Lab Limited Unsponsored ADR (ZLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

A strong phase-3 clinical trial boosted investors' hopes for the Chinese biotech company.

Zai Lab Ltd - ADR ZLAB shares are trading higher by 7.04% to $33.01 Wednesday morning. Shares of Chinese companies at large are trading higher after Chinese regulators reportedly approved a capital raise for Ant Group.

SHANGHAI, China and CAMBRIDGE, Mass., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that senior management from Zai Lab will participate in the following investor conferences in January 2023:

Zai Lab Limited is a relative new entrant to the Chinese pharma space and has multiple approvals and a large clinical pipeline. Founder Samantha Du seems willing and capable at driving commercialization partnerships with foreign entities.

Zai Lab Limited (NASDAQ:ZLAB ) Q3 2022 Results Conference Call November 10, 2022 8:00 AM ET Company Participants Billy Cho - Chief Financial Officer Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - Chief Operating Officer Harald Reinhart - President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases Jonathan Wang - Chief Business Development Conference Call Participants Michael Yee - Jefferies Yigal Nochomovitz - Citi Anupam Rama - J.P. Morgan Ziyi Chen - Goldman Sachs Jonathan Chang - SVB Leerink Seamus Fernandez - Guggenheim Operator Hello, ladies and gentlemen.

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will participate in the following investor conferences in November:

-- Company to Host Conference Call and Webcast on November 10, 2022, at 8:00 a.m. ET -- Company to Host Conference Call and Webcast on November 10, 2022, at 8:00 a.m. ET

New subgroup analysis of the Phase 3 PRIME study reveals improvement in efficacy outcomes for ZEJULA® (niraparib) maintenance treatment when started within 12 weeks after first-line platinum-based chemotherapy (1LCT) New subgroup analysis of the Phase 3 PRIME study reveals improvement in efficacy outcomes for ZEJULA® (niraparib) maintenance treatment when started within 12 weeks after first-line platinum-based chemotherapy (1LCT)

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will participate in the following investor conferences in September: